Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (218)
  2. Journal Article (126)
  3. Review (18)
  4. Research Letter (7)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (2)
Groups
  1. Adult Leukemia (378)
  2. Center for Hematologic Malignancies (378)
  3. Department of Medicine (378)
  4. Hematologic Malignancies, Division of (378)
  5. GSK Faculty (188)
  6. Hematologic Malignancies Research (145)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (85)
  3. Maria Palomba (84)
  4. Michel Sadelain (84)
  5. Martin Tallman (81)
  6. Miguel-Angel Perales (72)

More People

Years
  1. 2025 (26)
  2. 2024 (38)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (147)
  2. Journal of Clinical Oncology (31)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (161)
  2. Elsevier Inc. (35)
  3. American Society of Clinical Oncology (33)
  4. Nature Publishing Group (30)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (378)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Target densities in malignant and normal cells determine CAR T cell efficacy and off-target hematotoxicity
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; De Stanchina, E.; Fraser, K.; Park, J. H.; Wang, X.; Rivière, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The role of allogeneic transplant for adult Ph(+) ALL in CR1 with complete molecular remission: A retrospective analysis
    Journal Article

    Ghobadi, A.; Slade, M.; Kantarjian, H.; Alvarenga, J.; Aldoss, I.; Mohammed, K. A.; Jabbour, E.; Faramand, R.; Shah, B. J.; Locke, F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Journal Article

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
    Review

    Ravandi, F.; Kreitman, R. J.; Tiacci, E.; Andritsos, L.; Banerji, V.; Barrientos, J. C.; Bhat, S. A.; Blachly, J. S.; Broccoli, A.; Call, T.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
    Journal Article

    Handa, S.; Lee, J. O.; Derkach, A.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Shukla, M.; Vemuri, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 study of itacitinib for the prevention of cytokine release syndrome (CRS) induced by immune effector cell (IEC) therapy: Preliminary results
    Meeting Abstract

    Frigault, M. J.; Maziarz, R. T.; Lazaryan, A.; Frey, N. V.; Assal, A.; Shah, N. N.; Lekakis, L. J.; Park, J. H.; Phillips, C. L.; Burke, L.; more...
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save